WJB001 + niraparib

WJB001 + niraparib is an experimental **combination therapy** consisting of WJB001 (an investigational drug) and **niraparib**, a well-characterized **PARP inhibitor** approved for the maintenance treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancers and in combination therapies for metastatic castration-resistant prostate cancer. Niraparib works by inhibiting the **poly (ADP-ribose) polymerase (PARP1 and PARP2)** enzymes, leading to impaired DNA repair in cancer cells, especially those with defects in homologous recombination repair mechanisms such as BRCA mutations[2][5][7]. There is currently no publicly available detailed information on WJB001’s mechanism, developer, or clinical status in combination with niraparib.